

# Impact of delisting OTC medicines from reimbursement list

Petra Chytilová, Robin Šebesta

State Institute for Drug Control, SÚKL, Prague, Czech Republic

## Problem Statement

Over-the-Counter medicines (OTCs) were excluded from reimbursement by law since July 1, 2012. Selected OTCs remained reimbursed with the approval of insurance funds, usually under certain conditions of reimbursement (for specific indications or patient groups).

## Methodology




SÚKL's list of reimbursed medicines valid as of June 1, 2012 was compared to the list of reimbursed medicines valid as of July 1, 2012 to identify OTCs excluded from reimbursement. The financial impact of delisting OTCs was calculated based on consumption data and reimbursement price from the payers. The current reimbursement list (May 2015) was searched to identify the current spectrum of reimbursed OTCs.

## Results

There were 238 reimbursed OTCs in June 2012 and 14 OTCs remained reimbursed in July 2012. The reimbursement is limited by conditions of reimbursement for most of reimbursed OTCs. The delisted OTCs saved payers approx. 21,6 mil € (1€ = 27,624 CZK) in the first year after the delisting. Average price of not excluded OTCs has grown to 12,54 % and average price of excluded OTCs has grown to 10,70 % since January 2012.

## Conclusion

Almost 95 % of previously reimbursed OTC medicines were excluded from the reimbursement system in 2012. OTC medicines that remain in the reimbursement system are reimbursed for example for patients with cystic fibrosis, diagnosed Sjogren's syndrome (dry eyes), chronic pancreatitis. The payers saved 21,6 mil. € due to the delisting. The delisting did not have a major impact on the price of excluded OTCs.



Reimbursed OTCs by ATC code		
7/2012	5/2015	
A09AA02 multienzymes	A09AA02 multienzymes	D02AC soft paraffin and fat products
B01AC06 Acetylsalicylic acid	B01AC06 Acetylsalicylic acid	D02AE01 carbamide
M01AE01 Ibuprofen (suspension)	S01XA20 Artificial tears and other indifferent preparations	R05CB06 ambroxol
S01XA20 Artificial tears and other indifferent preparations	A12AX calcium, combinations with vitamin D and/or other drugs	R06AE07 cetirizine